Lilly's Obesity Drug Eloralintide Meets Primary Goal In Phase 2 Study

(RTTNews) - Eli Lilly and Company (LLY) on Thursday announced positive results from a Phase 2 trial evaluating eloralintide in adults with obesity or overweight.

The study achieved its primary endpoint, showing mean weight reductions ranging from 9.5% to 20.1%, compared with 0.4% for placebo.

Lilly said it plans to initiate Phase 3 studies of eloralintide as a monotherapy for obesity treatment by the end of 2025.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.